Key Points
- Director David Greenberg sold 2,424 shares of ICU Medical stock at an average price of $122.91, reducing his holdings by 23.34% to 7,960 shares.
- ICU Medical reported stronger-than-expected quarterly results, posting EPS of $1.97 versus the $1.78 estimate and revenue of $525.77 million above forecasts, though revenue was still down 12.3% year over year.
- Analyst sentiment remains positive, with a consensus “Buy” rating and an average price target of $169.00, even as some firms trimmed their price targets in recent reports.
ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report) Director David Greenberg sold 2,424 shares of the company's stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total value of $297,933.84. Following the transaction, the director directly owned 7,960 shares in the company, valued at approximately $978,363.60. This represents a 23.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
ICU Medical Trading Down 1.0%
Shares of NASDAQ ICUI opened at $122.04 on Thursday. ICU Medical, Inc. has a fifty-two week low of $107.00 and a fifty-two week high of $160.29. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.17 and a current ratio of 2.34. The company has a market cap of $3.05 billion, a price-to-earnings ratio of 65.97, a PEG ratio of 1.78 and a beta of 0.74. The business's 50 day moving average price is $126.79 and its 200-day moving average price is $138.45.
ICU Medical (NASDAQ:ICUI - Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.78 by $0.19. The company had revenue of $525.77 million during the quarter, compared to analysts' expectations of $520.65 million. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.ICU Medical's revenue was down 12.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.72 EPS. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. On average, sell-side analysts expect that ICU Medical, Inc. will post 6.31 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on ICUI shares. Jefferies Financial Group upgraded shares of ICU Medical to a "strong-buy" rating in a report on Thursday, May 7th. Piper Sandler decreased their price objective on shares of ICU Medical from $178.00 to $163.00 and set an "overweight" rating for the company in a report on Friday, April 17th. KeyCorp lowered their price objective on shares of ICU Medical from $180.00 to $164.00 and set an "overweight" rating for the company in a research report on Monday, April 27th. Wall Street Zen upgraded shares of ICU Medical from a "hold" rating to a "buy" rating in a research note on Saturday, May 9th. Finally, Weiss Ratings raised shares of ICU Medical from a "sell (d)" rating to a "sell (d+)" rating in a research report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $169.00.
View Our Latest Stock Analysis on ICUI
Hedge Funds Weigh In On ICU Medical
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC increased its stake in shares of ICU Medical by 2.5% during the first quarter. AQR Capital Management LLC now owns 9,360 shares of the medical instruments supplier's stock valued at $1,297,000 after buying an additional 229 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in ICU Medical by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,764 shares of the medical instruments supplier's stock worth $1,772,000 after acquiring an additional 560 shares during the period. United Services Automobile Association bought a new position in ICU Medical during the 1st quarter worth about $218,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in ICU Medical by 32.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 68,211 shares of the medical instruments supplier's stock valued at $9,472,000 after purchasing an additional 16,680 shares during the period. Finally, Intech Investment Management LLC increased its position in ICU Medical by 38.6% during the 1st quarter. Intech Investment Management LLC now owns 11,938 shares of the medical instruments supplier's stock valued at $1,658,000 after purchasing an additional 3,326 shares during the period. Institutional investors own 96.10% of the company's stock.
About ICU Medical
(
Get Free Report)
ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
